Patents by Inventor Runlu Jia

Runlu Jia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone
    Patent number: 12642778
    Abstract: The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: June 2, 2026
    Assignee: CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd
    Inventors: Chunlei Li, Xuefang Xia, Yanhui Li, Na An, Yanling Du, Tong Li, Shixia Wang, Runlu Jia
  • USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME AND CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE
    Publication number: 20240024257
    Abstract: The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.
    Type: Application
    Filed: August 26, 2021
    Publication date: January 25, 2024
    Inventors: Chunlei Li, Xuefang Xia, Yanhui Li, Na An, Yanling Du, Tong Li, Shixia Wang, Runlu Jia